HC Wainwright Reaffirms Buy Rating for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $17.00 target price on the biotechnology company’s stock.

Separately, StockNews.com assumed coverage on shares of Curis in a report on Friday. They set a “hold” rating for the company.

Curis Price Performance

NASDAQ CRIS opened at $2.03 on Monday. The company’s fifty day moving average is $1.92 and its two-hundred day moving average is $2.97. The firm has a market capitalization of $21.24 million, a price-to-earnings ratio of -0.26 and a beta of 3.65. Curis has a 52-week low of $1.02 and a 52-week high of $11.90.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.14) by ($0.11). The business had revenue of $2.38 million for the quarter, compared to the consensus estimate of $2.37 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. During the same period in the previous year, the business posted ($2.05) earnings per share. As a group, sell-side analysts expect that Curis will post -7.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Curis

A number of hedge funds and other institutional investors have recently made changes to their positions in CRIS. XTX Topco Ltd bought a new position in shares of Curis during the 1st quarter worth about $27,000. Squarepoint Ops LLC bought a new position in Curis during the 4th quarter valued at about $35,000. Millennium Management LLC lifted its holdings in Curis by 92.6% during the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 12,287 shares during the last quarter. Focused Wealth Management Inc lifted its holdings in Curis by 9.5% during the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after purchasing an additional 5,138 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Curis by 27.3% during the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 17,820 shares during the last quarter. 29.97% of the stock is owned by institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.